Codexis Enters Into Research Collaboration With Schering-Plough
Advertisement
Codexis, Inc. announced that it has signed a research agreement with Schering-Plough Corporation to develop a novel synthetic process for use by Schering-Plough. The collaboration will focus on improving biocatalyst productivity using Codexis' proprietary MolecularBreeding(TM) pharmaceutical process re-engineering platform. Codexis will receive research funding and milestone payments upon successful completion of certain objectives of the research. Further terms were not disclosed.
According to Codexis, the company's unique MolecularBreeding(TM) protein and strain engineering technology platform creates superior biological catalysts (biocatalysts) -- either enzymes or fermentation strains -- crafted specifically for cutting-edge chemical processes that can enable pharmaceutical process development, shorten process development timelines, dramatically improve existing manufacturing processes and increase chemical development productivity. Codexis estimates that its platform technology can reduce cost of goods by 35% - 65% and capital expenditures by over 35%. In addition, this platform technology can create new intellectual property opportunities, which can help extend the lifetime of drug products.
Most read news
Topics
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Lilly to expand injectable manufacturing capacity with planned $2.5 billion site in Germany - Company also commits to investing up to $100 million in German early-stage life sciences ecosystem
QIAGEN Expands Partnership with Genome Diagnostics for Development of Tests in Prevention and Personalized Healthcare - Extended HLA testing portfolio includes products to assess tolerance for Lumiracoxib and for the early detection of inflammatory diseases
Codexis Opens Singapore Laboratory
Nail_disease
